Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Hideo Morioka, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Mitsuru Takahashi, Tsukasa Yonemoto, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Michiro Susa, Robert Nakayama, Kazumasa Nishimoto, Kazutaka Kikuta, Keisuke Horiuchi, Akira Kawai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive care(BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of trabectedin for EMCS and MCS subjects in the randomized phase 2 study. Methods: Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study. Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology imaging review. Results: The median follow-up time of the randomized phase 2 study was 22.7months, and one subject with MCS was still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5months (95 % CI: 7.4-not reached) in the trabectedin group, while 1.0months (95 % CI: 0.3-1.0months) in MCS subjects of the BSC group. The six-month progression-free rate was 100% in the trabectedin group. One subject with MCS showed partial response, and the others in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4months (range, 10.4-26.4months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive. Conclusions: This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC. The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard chemotherapy. Trial registration: The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121850(May 31, 2012).

Original languageEnglish
Article number479
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - Jul 14 2016

Fingerprint

trabectedin
Mesenchymal Chondrosarcoma
Therapeutics
Sarcoma
Disease-Free Survival
Extraskeletal Myxoid Chondrosarcoma

Keywords

  • Chemotherapy
  • Extraskeletal myxoid chondrosarcoma
  • Mesenchymal chondrosarcoma
  • Trabectedin
  • Translocation-related sarcoma

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. / Morioka, Hideo; Takahashi, Shunji; Araki, Nobuhito; Sugiura, Hideshi; Ueda, Takafumi; Takahashi, Mitsuru; Yonemoto, Tsukasa; Hiraga, Hiroaki; Hiruma, Toru; Kunisada, Toshiyuki; Matsumine, Akihiko; Susa, Michiro; Nakayama, Robert; Nishimoto, Kazumasa; Kikuta, Kazutaka; Horiuchi, Keisuke; Kawai, Akira.

In: BMC Cancer, Vol. 16, No. 1, 479, 14.07.2016.

Research output: Contribution to journalArticle

Morioka, H, Takahashi, S, Araki, N, Sugiura, H, Ueda, T, Takahashi, M, Yonemoto, T, Hiraga, H, Hiruma, T, Kunisada, T, Matsumine, A, Susa, M, Nakayama, R, Nishimoto, K, Kikuta, K, Horiuchi, K & Kawai, A 2016, 'Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma', BMC Cancer, vol. 16, no. 1, 479. https://doi.org/10.1186/s12885-016-2511-y
Morioka, Hideo ; Takahashi, Shunji ; Araki, Nobuhito ; Sugiura, Hideshi ; Ueda, Takafumi ; Takahashi, Mitsuru ; Yonemoto, Tsukasa ; Hiraga, Hiroaki ; Hiruma, Toru ; Kunisada, Toshiyuki ; Matsumine, Akihiko ; Susa, Michiro ; Nakayama, Robert ; Nishimoto, Kazumasa ; Kikuta, Kazutaka ; Horiuchi, Keisuke ; Kawai, Akira. / Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{07c5946c98aa4200b825484a09887681,
title = "Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma",
abstract = "Background: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive care(BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of trabectedin for EMCS and MCS subjects in the randomized phase 2 study. Methods: Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study. Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology imaging review. Results: The median follow-up time of the randomized phase 2 study was 22.7months, and one subject with MCS was still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5months (95 {\%} CI: 7.4-not reached) in the trabectedin group, while 1.0months (95 {\%} CI: 0.3-1.0months) in MCS subjects of the BSC group. The six-month progression-free rate was 100{\%} in the trabectedin group. One subject with MCS showed partial response, and the others in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4months (range, 10.4-26.4months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive. Conclusions: This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC. The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard chemotherapy. Trial registration: The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121850(May 31, 2012).",
keywords = "Chemotherapy, Extraskeletal myxoid chondrosarcoma, Mesenchymal chondrosarcoma, Trabectedin, Translocation-related sarcoma",
author = "Hideo Morioka and Shunji Takahashi and Nobuhito Araki and Hideshi Sugiura and Takafumi Ueda and Mitsuru Takahashi and Tsukasa Yonemoto and Hiroaki Hiraga and Toru Hiruma and Toshiyuki Kunisada and Akihiko Matsumine and Michiro Susa and Robert Nakayama and Kazumasa Nishimoto and Kazutaka Kikuta and Keisuke Horiuchi and Akira Kawai",
year = "2016",
month = "7",
day = "14",
doi = "10.1186/s12885-016-2511-y",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

AU - Morioka, Hideo

AU - Takahashi, Shunji

AU - Araki, Nobuhito

AU - Sugiura, Hideshi

AU - Ueda, Takafumi

AU - Takahashi, Mitsuru

AU - Yonemoto, Tsukasa

AU - Hiraga, Hiroaki

AU - Hiruma, Toru

AU - Kunisada, Toshiyuki

AU - Matsumine, Akihiko

AU - Susa, Michiro

AU - Nakayama, Robert

AU - Nishimoto, Kazumasa

AU - Kikuta, Kazutaka

AU - Horiuchi, Keisuke

AU - Kawai, Akira

PY - 2016/7/14

Y1 - 2016/7/14

N2 - Background: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive care(BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of trabectedin for EMCS and MCS subjects in the randomized phase 2 study. Methods: Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study. Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology imaging review. Results: The median follow-up time of the randomized phase 2 study was 22.7months, and one subject with MCS was still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5months (95 % CI: 7.4-not reached) in the trabectedin group, while 1.0months (95 % CI: 0.3-1.0months) in MCS subjects of the BSC group. The six-month progression-free rate was 100% in the trabectedin group. One subject with MCS showed partial response, and the others in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4months (range, 10.4-26.4months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive. Conclusions: This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC. The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard chemotherapy. Trial registration: The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121850(May 31, 2012).

AB - Background: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive care(BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of trabectedin for EMCS and MCS subjects in the randomized phase 2 study. Methods: Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study. Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology imaging review. Results: The median follow-up time of the randomized phase 2 study was 22.7months, and one subject with MCS was still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5months (95 % CI: 7.4-not reached) in the trabectedin group, while 1.0months (95 % CI: 0.3-1.0months) in MCS subjects of the BSC group. The six-month progression-free rate was 100% in the trabectedin group. One subject with MCS showed partial response, and the others in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4months (range, 10.4-26.4months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive. Conclusions: This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC. The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard chemotherapy. Trial registration: The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121850(May 31, 2012).

KW - Chemotherapy

KW - Extraskeletal myxoid chondrosarcoma

KW - Mesenchymal chondrosarcoma

KW - Trabectedin

KW - Translocation-related sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84987704688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987704688&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2511-y

DO - 10.1186/s12885-016-2511-y

M3 - Article

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 479

ER -